Sofie Biosciences, an emerging in vivo imaging diagnostics company focused on PET probes, scanners and chemistry systems,announced today that the National Institute of Health has awarded the company a grant under the Small Business Innovation Research (SBIR) program.

A tau-imaging agent has moved ahead of the pack to pick up strong signals of tau aggregates in the brain in patterns consistent with Alzheimer’s disease (AD), according a study published Sept. 18 in Neuron.

Only one amyloid PET scan will be covered to aid in the diagnosis of Alzheimer’s disease (AD), according to an official CMS decision on Friday.

At the 55th American Society for Radiation Oncology ASTRO annual meeting, Sept. 22-25 in Atlanta, Royal Philips will feature the latest innovations that address efficient and personalized radiation oncology care for patients and their clinicians.

Cancer screening with amino acid PET has already been validated for adults, but it has now been deemed a powerful tool for tumor localization in children and young adults, according to a study published Sept. 19 in the Journal of Nuclear Medicine.

Visualization of Parkinson’s disease (PD) development may now be possible by identifying dopaminergic nigrosomes, or the lack thereof, according to a study published Aug. 6 in Neurology

The 2013 World Molecular Imaging Congress (WMIC) held Sept. 18-21 in Savannah, Ga., highlighted biomarker clinical trials, diabetes and brain research, advances in technology and a program that encouraged emerging experts, say World Molecular Imaging Society leaders in an exclusive interview with Molecular Imaging.

Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved PET radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.